top of page
Gotham__Org Gotham White.png

National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 17 Item Version

For patients with Prostate cancer; a FACT/NCCN-Prostate Symptom Index



Below are the details for the NFPSI-17 measure:


National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 17 Item Version (NFPSI-17)






Prostate cancer patients 18 years and older


Past 7 days


5 point Likert-type scale


Paper and electronic


Self-administration and interview when applicable


Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side-Effects, Function/Well-Being


5-10 minutes


Manual scoring template, some items are reverse scored. Subscale scores and total scores possible.


Language Availability

Available translations of the NFPSI-17 can be obtained by registering for permission. Users are not permitted to translate the NFPSI-17 without permission from Permission from to translate the NFPSI-17 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.

Please contact us for more information.

Language Availability


Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.

Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.

To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.

Selected References

Selected References

Beaumont, J., Butt, Z., Li, R., & Cella, D.  Meaningful Differences and Validity for the NCCN/FACT-P Symptom Index: An analysis of the ALSYMPCA data.  Cancer 2019; 125(11): 1877-1885.  doi: 10.1002/cncr.31973. 

Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J.  What are the most important symptom targets when treating advanced cancer?  A survey of providers in the National Comprehensive Cancer Network (NCCN).  Cancer Investigation 2003; 21(4): 526-535.  doi: 10.108/CNV-120022366.  

Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J.  Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer.  Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. 

Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., & Cella, D.  Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.).  The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research.  Emerald Group Publishing Inc. 2007; 16: 53-66.  doi: 10.1016/S0194-3960(08)16003-6. 

Satapathy, S., Mittal, B., Sood, A. et al. 177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. Eur J Nucl Med Mol Imaging (2021).

Satapathy S, Mittal BR, Sood A, Das CK, Singh SK, Mavuduru RS, et al. Health-related quality-of-life outcomes with actinium-225-prostatespecific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer. Indian J Nucl Med 2020;35:299-304.

Victorson, D., Beaumont, J., Rosenbloom, S., Shevrin, D., & Cella, D.  Efficient assessment of the most important symptoms in advanced prostate cancer: The NCCN/FACT-P symptom index.  Psycho-Oncology 2011; 20(9): 977-983.  doi: 10.1002/pon.1817.

Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R.  Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system.  Quality of Life Research 1996; 5: 309-320.

Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.

Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.

Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.

Related Measures

Related Measures


Functional Assessment of Cancer Therapy – Prostate


Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 7 Item Version


Functional Assessment of Cancer Therapy – Radionuclide Therapy

bottom of page